NCT07189455

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 420 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Conditions

• Small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	ZG006	ZG006 will be administered as an intravenous (IV) infusion.
DRUG	Topotecan	Topotecan will be administered per local standard of care

Timeline

• Start date: 2025-12-12
• Primary completion: 2028-10-01
• Completion: 2028-12-01
• First posted: 2025-09-24
• Last updated: 2026-01-05

Locations

1 site across 1 country: China